deltatrials

Shire Clinical Trials

Sponsors / Shire

352 ClinicalTrials.gov entries name Shire as the lead sponsor. Of these, 3 are recruiting, 2 are active without new recruitment, and 296 have completed. The registry records 46 terminated or withdrawn trials for Shire. The most common reasons cited for termination include safety concerns, business or strategic decisions, efficacy or futility findings. Planned participant enrollment across these trials sums to 81,369. Figures on this page are sourced from ClinicalTrials.gov and refreshed with each registry update.

352
Total Trials
3
Recruiting
2
Other Active
296
Completed
46
Terminated / Withdrawn
81,369
Total Enrollment

Termination reasons: Safety30% · Business17% · Efficacy17% · Other17% · Recruitment15% · Funding2%

Recent Terminations

  • NCT04840667 Phase PHASE3 Stopped Dec 2022
    Fabry Disease
    "Study closed due to enrolment challenges, not for any safety issues"
  • NCT04094181 Stopped Nov 2021
    Gaucher Disease
    "The decision was taken after careful consideration relating to recruitment challenges that could impact the scientific value of the study."
  • NCT03627091 Phase PHASE3 Stopped Sep 2021
    Crohn's Disease
    "Sponsor decision to discontinue the SHP647 (ontamalimab) clinical trial development program for inflammatory bowel diseases (IBD) early."
  • NCT03259334 Phase PHASE3 Stopped Oct 2020
    Ulcerative Colitis
    "Sponsor decision to discontinue the SHP647 (ontamalimab) clinical trial development program for inflammatory bowel diseases (IBD) early."
  • NCT03559517 Phase PHASE3 Stopped Oct 2020
    Crohn's Disease
    "Sponsor decision to discontinue the SHP647 (ontamalimab) clinical trial development program for inflammatory bowel diseases (IBD) early."
  • NCT03259308 Phase PHASE3 Stopped Oct 2020
    Ulcerative Colitis
    "Sponsor decision to discontinue the SHP647 (ontamalimab) clinical trial development program for inflammatory bowel diseases (IBD) early."
  • NCT03566823 Phase PHASE3 Stopped Aug 2020
    Crohn's Disease
    "Sponsor decision to discontinue the SHP647 (ontamalimab) clinical trial development program for inflammatory bowel diseases (IBD) early."
  • NCT03364738 Phase PHASE3 Stopped Apr 2020
    Hypoparathyroidism
    "The study was terminated due to Takeda commercial Natpara recall."
  • NCT04131556 Phase PHASE1 Stopped Jan 2020
    Healthy Volunteers
    "The study was stopped because based on the planned interim analysis of the data of Part 1, palatability of both pediatric formulations was not acceptable."
  • NCT03325894 Phase PHASE3 Stopped Jan 2019
    Attention Deficit Hyperactivity Disorder (ADHD)
    "The study was stopped due to efficacy reasons."

Active Trials (2 total)

Top Conditions

Hereditary angioedema (hae) (22) Healthy (19) Attention deficit hyperactivity disorder (adhd) (15) Short bowel syndrome (13) Fabry disease (12) Healthy volunteers (12) Hunter syndrome (11) Ulcerative colitis (11) ADHD (10) Attention deficit disorder with hyperactivity (10)

Top Locations

Houston, United States (84) New York, United States (82) Chicago, United States (65) Cincinnati, United States (65) Atlanta, United States (59) Philadelphia, United States (59) San Antonio, United States (58) Orlando, United States (57) Las Vegas, United States (51) San Diego, United States (50)